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Abstract
Mesial temporal lobe epilepsy is the most common form of adult epilepsy in surgical series.
Currently, the only characteristic used to predict poor response to clinical treatment in this
syndrome is the presence of hippocampal sclerosis. Single nucleotide polymorphisms
(SNPs) located in genes encoding drug transporter and metabolism proteins could influence
response to therapy. Therefore, we aimed to evaluate whether combining information from
clinical variables as well as SNPs in candidate genes could improve the accuracy of predict-
ing response to drug therapy in patients with mesial temporal lobe epilepsy. For this, we
divided 237 patients into two groups: 75 responsive and 162 refractory to antiepileptic
drug therapy. We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1,
CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. We used 98 addi-
tional SNPs to evaluate population stratification. We assessed a first scenario using only
clinical variables and a second one including SNP information. The random forests algo-
rithm combined with leave-one-out cross-validation was used to identify the best predictive
model in each scenario and compared their accuracies using the area under the curve sta-
tistic. Additionally, we built a variable importance plot to present the set of most relevant pre-
dictors on the best model. The selected best model included the presence of hippocampal
sclerosis and 56 SNPs. Furthermore, including SNPs in the model improved accuracy from
0.4568 to 0.8177. Our findings suggest that adding genetic information provided by SNPs,
located on drug transport and metabolism genes, can improve the accuracy for predicting
which patients with mesial temporal lobe epilepsy are likely to be refractory to drug treat-
ment, making it possible to identify patients who may benefit from epilepsy surgery sooner.
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Introduction
Mesial temporal lobe epilepsy (MTLE) is the most common form of epilepsy in adults, and it is
frequently associated with hippocampal sclerosis (HS), which can be detected by magnetic res-
onance imaging (MRI) [1, 2]. A high proportion of patients with MTLE is refractory to drug
treatment with antiepileptic drugs (AEDs), and the presence of HS has been used to predict
poor AED response in these patients [1]. However, other factors have been implicated in AED
drug response (yet not proven), such as gender, age of seizure onset, aetiology of epilepsy, as
well as genetic factors including family history of epilepsy and gene mutations affecting pro-
teins involved in AED absorption, metabolism, and transport [3].
Some AEDs, such as phenytoin (PHT) and carbamazepine (CBZ), are substrates for adeno-
sine triphosphate-binding cassette transporter proteins (ABC) [4, 5]. ABC genes encode multi-
drug resistance proteins, and previous studies have suggested that multidrug resistance
proteins could decrease drug penetration into the brain of patients with refractory MTLE [4,
6], leading to pharmacoresistance. In fact, studies showed an increase in ABCB1 and ABCC2
protein expression in endothelial cells from temporal lobe blood vessels of patients with refrac-
tory MTLE [6, 7], and a higher ABCB1 protein activity was observed in hippocampus of
patients with pharmacoresistant temporal lobe epilepsy [8]. In addition, because PHT and
CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have
an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19,
CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins [9–13].
Genetic studies have demonstrated that single nucleotide polymorphisms (SNPs) located in
the ABCB1 (rs1045642) and ABCC2 genes (rs2273697, rs717620 and rs3740066) could be asso-
ciated with refractory epilepsy [14, 15]. However, subsequent studies did not replicate these
findings [16, 17]. Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated
with PHT dose requirement [18, 19], and SNPs in CYP2C19 (rs12248560) and CYP2D6 have
been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic
drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. Food
and Drug Administration (FDA) [19]. In addition, studies have showed association between
rs2606345 in CYP1A1 gene and North Indian women with epilepsy [20], and between rs762551
in CYP1A2 and CBZ pharmacokinetics in children diagnosed with partial or generalized tonic-
clonic seizures [21]. However, none of these pharmacogenetic variables have been proven to be
useful for predicting response to AEDs in patients with MTLE [22]. In this context, the objective
of this study was to evaluate whether SNPs in the following genes—ABCB1,ABCC2,CYP1A1,
CYP1A2,CYP1B1,CYP2C9,CYP2C19,CYP2D6,CYP2E1,CYP3A4, and CYP3A5—could
improve the accuracy of predicting poor response to AED therapy in patients with MTLE.
Methods
Subjects and clinical evaluation
The Research Ethics Committee of our institution (Comitê de E´tica em Pesquisa da Universi-
dade Estadual de Campinas–UNICAMP) approved this study and all 237 participants signed a
consent form before entering the study. We assessed consecutive patients with MTLE (103
males) classified according to the International League Against Epilepsy (ILAE) criteria [23].
We followed all patients regularly from 2006 to 2015 at the outpatient epilepsy clinic of the
University of Campinas-(UNICAMP) hospital, which is a tertiary centre for epilepsy, and in a
community outpatient clinic in Campinas, Brazil. Two investigators (MSS and EB) inter-
viewed all patients and collected information using structured questionnaire gathering infor-
mation regarding age and frequency of seizures at epilepsy onset, febrile seizures (FS),
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presence of initial precipitating injuries (IPIs), and number of AEDs. In addition, all patients
underwent a neurological exam, serial interictal EEGs with a duration of at least 35 minutes,
and high resolution MRI epilepsy protocol, including thin (3mm or less) T1 and T2 sequences
in the axial, coronal and sagittal planes as well as a 3D T1-weighted acquisition with 1mm iso-
tropic voxels in a 2T (Elscint Prestige, Haifa, Israel) or 3T (Philips Intera Achieva, Best, the
Netherlands) scanner [24]. All data were reviewed by a senior epileptologist (FC).
MTLE was defined based on a constellation of signs and symptoms, with the characteristic
seizure semiology, including viscerosensory or experiential auras, such as rising epigastric sen-
sation, fear, de´jà vu, jamais vu, dreamy state, with or without autonomic symptoms (e.g. flush-
ing, pallor, tachycardia), frequently followed by dyscognitive seizures with staring, oral, verbal,
or gestural automatisms (e.g., lip smacking, chewing) with a progressive clouding of con-
sciousness, sometimes with dystonic posture of the contralateral hand [23, 25]. Interictal EEG
studies presented either lateralised anterior or middle temporal epileptiform activity or no epi-
leptiform abnormalities and normal background. Patients with extratemporal epileptiform or
non-epileptiform abnormalities were not selected. Video-EEG for seizure recording, neuro-
psychological tests and positron emission tomography (PET) or ictal single photon emission
computed tomography (SPECT) were performed in a subset of patients; in particular, those
with refractory seizures, unclear interictal EEGs and negative MRIs.
Hippocampal atrophy and other MRI signs of HS were assessed by visual analyses by two
epilepsy imaging experts (CLY and FC) and the images were classified as having normal find-
ings or signs of HS. Classic signs of HS were as follows: reduction of volume and/or abnormal
shape observed on T1-weighted images, with or without increased signal observed in
T2-weighted and FLAIR images [25]. Special attention was given to rule out subtle signs of
other lesions, such as focal cortical dysplasia, tumours or gliotic scars. Patients with dual
pathology or other MRI abnormalities were not included. In addition, hippocampal volumetry
was performed in all patients and compared to a group of 79 healthy controls (with similar age
and sex distribution) with FreeSurfer software v.5.1.0 (http://surfer.nmr.mgh.harvard.edu), as
previously described [24]. Therefore, the presence of MRI findings of HS or normal MRI was
defined by results of visual analyses and automatic hippocampal volumetry.
We divided patients into two groups: 75 (32%) individuals were classified as AED respon-
sive MTLE and 162 (68%) were classified as refractory MTLE. AED responsive was defined as
freedom from all seizures, including auras, for a period of 12 months or at least three times the
previous longest seizure-free interval, whichever was longer, according to the recent definition
of the ILAE [26]. Refractory MTLE included patients who failed to achieve sustained seizure
freedom, after two or more trials of tolerated and appropriately chosen AED schedules in
monotherapies or in combination [26].
SNP selection
In order to represent variability across candidate genes, we perform a systematically SNPtag
selection using SNPBROWSERTM v.4.0 software (Applied Biosystems, Foster City, California,
USA), based on the International HapMap Project (http://hapmap.ncbi.nlm.nih.gov/), a mini-
mum allele frequency (MAF)>0.05, and a pairwise linkage disequilibrium (LD) of r2>0.8. In
this case, we did not include intentionally the SNPs previously reported because it could lead
to a bias in SNPtag candidate gene screening. Even so, the systematic selection led to the inclu-
sion of four previously reported ones (rs1045642; rs2273697; rs3740066; rs1057910), among
119 selected SNPs for the analysis.
Furthermore, we used an additional 98 SNPs for population stratification analysis, since 98
slots were available from 48-Plex kits in our laboratory, and previous studies showed that any
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number of SNPs greater than 65 is adequate to evaluate population stratification [27]. How-
ever, since the human genome contains a high density of SNPs, we developed a bioinformatics
pipeline to select randomly SNPs for the population stratification analysis. Briefly, using the
International HapMap Project, a SNP frequency vector was built based on the following
parameters: MAF>0.05, and minimum distance between two SNPs = 300 kb, which avoid pos-
sible LD [28]. In the next step, the pipeline uses the ‘sample’ function in R software v.3.2.3
(http://www.r-project.org) to select randomly 98 SNPs from the SNP frequency vector. We
concentrated SNP selection on chromosomes 2, 7, 10, 15 and 22 (Fig 1A), which harbour the
candidate gene analysed, since previous studies showed that population structure could vary
among chromosomes. These differences could be due to the presence of natural selection
imprint observed in many regions across the genome, thus creating substantial variation and
affecting the degree of variance inflation for specific loci, which leads to biased analyses [29].
SNPs genotyping
We obtained genomic DNA from patients peripheral blood using standard procedure [30],
and quantified using NanoVue V1.7.2 Spectrophotometer (GE Healthcare, Chicago, Illinois,
USA). In order to genotype the SNPs, we used the SNPlexTM Genotyping System 48-plex tech-
nology and ABI3730xl equipment (Applied Biosystems, Foster City, CA, USA). We used the
GeneMapper v.4.0 Software (Applied Biosystems, Foster City, CA, USA) to identify the SNP
genotypes from fluorescence signals.
ABCC2 mRNA quantification
We obtained total RNA from hippocampal tissue that had been surgically removed from 11
patients with refractory MTLE who underwent epilepsy surgery and had histopathology con-
firming HS. Among them, nine were also included in the SNP genotyping study. All 11
patients had pre-surgical MRIs with sings of hippocampal sclerosis. In addition, we obtained
normal hippocampal tissue from six autopsies of patients who died of non-neurological-
related disorders. We extracted total RNA by Trizol1 protocol (Life Technologies, Carlsbad,
CA, USA), and assessed RNA quality by NanoVue spectrophotometer at 260/280 nm (GE
Healthcare, Buckinghamshire, UK). We quantified the transcripts in triplicate using RT-PCR
TaqMan1 System and ABI 7500 equipment (Applied Biosystems, Foster City, CA, USA). We
used a target ABCC2 assay (probe ID: Hs00166123_m1) and human 18S rRNA as an endoge-
nous control. We calculated the relative quantification using fluorescence signals by the com-
parative threshold cycle method [31].
Statistical and prediction analysis
We used R software to perform all statistical analyses. We compared categorical clinical vari-
ables (gender, febrile seizures, and presence of HS on MRI) using Fisher’s exact test, and Stu-
dents’ two sample t-test to compare mean age at onset of seizures between the two groups. We
evaluated the genotyped SNPs in terms of Hardy–Weinberg equilibrium (p-value > 0.01),
MAF>0.01 and pairwise LD (r2>0.8) by HAPLOVIEW v.4.2 software [32]. In order to evaluate
whether response and refractory population substructure is similar, we performed the Analysis
of Molecular Variance (AMOVA) by ARLEQUIN v3.5.1.2 software [33], using the 98 additional
SNPs as factors in the analysis. The AMOVA partitions the source of genetic variance into two
components: within-groups and between-groups, and measures the population differentiation
due to genetic structure by the fixation index (Fst). We considered Fst<0.05 as the absence of
population stratification [29], as well as the between-groups variance component< 0.7%,
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Fig 1. Chromosome location of candidate genes and SNPtag map. a) genes are indicated by the grey vertical bars and distribution of SNPs
used in the population structure are indicated by the red vertical bars; b) linkage disequilibrium estimates are presented in terms of pairwise r2
values. Values of r2 > 80 indicate linkage disequilibrium.
doi:10.1371/journal.pone.0169214.g001
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because this value was the smallest one found when comparing populations within regions
worldwide [34].
We coded the SNP genotypes as AA, AB and BB, where B represents the alternative allele.
To evaluate whether SNPs improve the accuracy of predicting refractory MTLE, we used three
different scenarios: one that takes into account only clinical variables, one including only SNP
genotypes, and a third that includes clinical variables and SNP genotypes combined.
We used the random forests approach to select the best predictive model [35], which is able
to handle big data with a large number of variables (SNPs and clinical data), but limited sample
size [35, 36]. Random forests have one parameter mtry that describes the number of randomly
selected variables used to build the classification trees. To estimate the best mixture of parame-
ters mtry for each of 5000 classification trees, we used the Leave-One-Out Cross-Validation
(LOOCV) [35]. This validation divides the sample in one group containing only one individual
(called test set) and another group containing the remained individuals (called training set).
The algorithm fits the model from the training set and predicts the test set based on the train-
ing set, repeating this step until all individuals were tested (n steps, where n = sample size). In
the end, we selected the best model identifying the mtry that maximises the area under the
curve (AUC) among the 5000 classification trees. In addition, each variable had its importance
rank within the model estimated in terms of mean decreased accuracy (MDA). The MDA
calculates the discriminatory accuracy using a set of predictor variables. Then, the algorithm
permutes (or excludes) one variable X from the variable set and calculates a second discrimina-
tory accuracy. We estimate MDA by the difference between the accuracy before and after per-
muting X. In this case, if the variable is important for the model, the discriminatory accuracy
decreases substantially, and the greater the accuracy of the random forest decreases due to the
permutation (or exclusion) of a single variable, the more important it is considered [35].
Results
Clinical evaluation
As shown in Table 1, 61.3% of responsive and 54.3% of refractory MTLE patients were female.
The mean age of seizure onset was 12.4 years old for responsive and 11.3 years old for refrac-
tory patients. In addition, most patients presented the first seizure before 20 years old. Among
the clinical variables, only the distribution of HS was different between patients with respon-
sive and refractory MTLE (Fisher’s exact test p-value<6.43e-06). Among patients, four did not
have any information regarding previous history of febrile seizure, and one could not recall
age at seizure onset; therefore, they were withdrawn from the prediction analysis. We used the
age of epilepsy onset as a categorical variable, classifying individuals in 10 groups based on five
year windows.
In addition, CBZ, PHT and CLB appeared as the main AED used in mono or polytherapy
among responsive and refractory patients. Notably, diazepam, nitrazepam, levetiracetam, and
lacosamide were less commonly used (Table 2). AED treatment information was acquired
based on pre-operative data for refractory patients who underwent surgery, and the sum of
percentages of polytherapy groups is higher than 100% because one individual could use more
than one drug. We provided detailed information for each patient in S1 and S2 Tables.
SNPs genotyping
The SNP average genotypes call rate was 91.7% (standard deviation = 4.7%) in the candidate
genes and 84.0% (standard deviation = 12.2%) for SNPs used in the population stratification
analysis. Among the 119 SNPs genotyped in the candidate genes, 23 were not in Hardy-Wein-
berg equilibrium or presented MAF<0.01. Additionally, 30 had genotype call rate<90.0% (S3
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Table). Therefore, we excluded these 53 SNPs from further analysis, remaining 38 patients
with responsive MTLE and 84 patients with refractory MTLE who presented 100% genotype
call rate and were suitable for prediction analysis (S1–S5 Tables). In addition, LD was observed
between rs2153628 and rs9332168 (r2 = 0.88) in the CYP2C9 gene, and between rs11597626
and rs12268020 (r2 = 0.84) in CYP2C19 in the remaining SNP set (Fig 1B). Among the 98 SNPs
Table 1. Descriptive statistics of the two groups of patients with MTLE.
Variable AED Responsive (n = 75) AED Refractory (n = 162) p–value
Gender Male 29 (38.7%) 74 (45.7%) 0.39
Female 46 (61.3%) 88 (54.3%)
Mean age of seizure onset (years) 12.4 (SD = 10.8) 11.3 (SD = 8.5) 0.52
Age of seizure onset distributed by groups (range in years) 1 (0–5) 23 (30.7%) 52 (32.1%) 0.18
2 (6–10) 12 (16.0%) 30 (18.6%)
3 (11–15) 17 (22.7%) 35 (21.6%)
4 (16–20) 10 (13.3%) 22 (13.6%)
5 (21–25) 3 (4.0%) 13 (8.0%)
6 (26–30) 5 (6.7%) 6 (3.7%)
7 (31–35) 2 (2.7%) 1 (0.6%)
8 (36–40) 1 (1.3%) 1 (0.6%)
9 (41–45) 1 (1.3%) 1 (0.6%)
10 (> 46) 1 (1.3%) 0 (0.0%)
Unknown 0 (0.0%) 1 (0.6%)
Febrile seizures Yes 16 (21.3%) 35 (21.6%) 1.00
No 58 (77.3%) 124 (76.5%)
Unknown 1 (1.4%) 3 (1.9%)
Hippocampal sclerosis Yes 50 (66.7%) 148 (91.4%) 6.43e-06
No 25 (33.3%) 14 (8.6%)
AED, antiepileptic drug; SD, standard deviation.
doi:10.1371/journal.pone.0169214.t001
Table 2. Percentage that each AED appears in monotherapy or polytherapy in the responsive and refractory patients.
AED Monotherapy Polytherapy
Responsive (total = 30) Refractory (total = 29) Responsive (total = 45) Refractory (total = 133)
Carbamazepine 70.0% 100.0% 62.2% 81.2%
Phenitoin 13.3% 0.0% 28.9% 9.0%
Phenobarbital 16.7% 0.0% 22.2% 4.5%
Clobazam 0.0% 0.0% 44.4% 64.7%
Valproic acid 0.0% 0.0% 4.4% 8.3%
Topiramate 0.0% 0.0% 6.7% 7.5%
Lamotrigine 0.0% 0.0% 8.9% 11.3%
Oxcarbazepine 0.0% 0.0% 0.0% 3.8%
Clonazepam 0.0% 0.0% 2.2% 3.0%
Diazepam 0.0% 0.0% 2.2% 0.7%
Nitrazepam 0.0% 0.0% 0.0% 0.7%
Levetiracetam 0.0% 0.0% 0.0% 0.7%
Lacosamide 0.0% 0.0% 0.0% 0.7%
AED, antiepileptic drug.
doi:10.1371/journal.pone.0169214.t002
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selected for population stratification analysis, 20 were not in Hardy-Weinberg equilibrium or
presented an MAF<0.01, and 65 had a genotype call rate<90.0% (S4 Table). However, we only
excluded 20 SNPs of the population stratification analysis, since the locus-by-locus AMOVA is
robust for dealing with missing data [33]. As shown in Table 3, we observed Fst<0.05 for both
chromosomes combined and separated. In addition, population stratification analysis estimated
between-groups variance component of 0.3% for all five of the chromosomes combined, in-
dicating that the two groups did not present differences in genetic structure with each other.
Genotypes for all individuals included in this study are available in the supporting material
accompanying this paper and will be deposited in a public genomic database (www.bipmed.org).
Prediction analysis
The accuracy for identify a patient with refractory MTLE using only clinical information was
0.4568 (mtry = 2; sensitivity = 95.24; specificity = 0.00; Fig 2). However, after including SNPs in
Table 3. Fst values from the sample for all five chromosomes combined and separated. The table also includes the percentage of genetic variation
between and within groups.
Chromosome Source of variation (%) Fst
Within-groups Between-groups
Combined 99.7 0.3 0.003
2 100.0 0.0 0.000
7 100.0 0.0 0.000
10 99.8 0.2 0.002
15 99.0 1.0 0.010
22 97.5 2.5 0.025
doi:10.1371/journal.pone.0169214.t003
Fig 2. ROC curve showing the true positive rate (sensitivity), in function of false positive rate
(1-specificity). The blue line indicates the prediction scenario using only clinical variables (hippocampal sclerosis,
age of onset epilepsy, febrile seizures, and gender). The red line indicates the second scenario using the clinical
variables plus SNPs. The dark green line indicates the scenario using only SNP genotypes. The area under the
curve (AUC) values is showed for the three scenarios. The diagonal dashed line indicates a non-informative
prediction (AUC = 0.5).
doi:10.1371/journal.pone.0169214.g002
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the model, accuracy increased to 0.8177 (mtry = 16; sensitivity = 95.24; specificity = 21.05; Fig
2). Interestingly, the model that evaluated the contribution of SNPs alone reached an accuracy
of 0.8008 (mtry = 88; sensitivity = 36.84; specificity = 88.37; Fig 2). We show in the variance
important plot (Fig 3) the 15 most important genotypes from eight genes, which presented a
MDA>10 (a complete list of all genotype results is showed in S5 Table). As illustrated in Fig 3,
SNP rs2472306 in CYP1A2was the most important variable in the prediction model
(MDA = 25.3), followed by the presence of HS on MRI (MDA = 25.2).
ABCC2 mRNA expression in hippocampal tissue
Among the top SNPs present in the best prediction model, the fourth most important variable
for the model (rs2756104) is located in ABCC2, prompting us to analyse mRNA expression in
the hippocampal tissue of patients with refractory MTLE who underwent epilepsy surgery. Our
results clearly show the increased expression of ABCC2mRNA in hippocampal tissue from
patients when compared to autopsy controls (Wilcoxon rank sum test p-value = 0.02, Fig 4).
Discussion
We show in this study that SNP information from genes influencing drug metabolism and
drug transporters, together with clinical data, can significantly improve the prediction of
response to AEDs in patients with MTLE, with an estimated accuracy of 0.8177. In addition,
the most important variables in the prediction model include SNPs in ABCC2,CYP1A2,
CYP1B1,CYP2E1,CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which
have been previously proposed as pharmacogenetic biomarkers [19].
Approximately 30.0% of patients with MTLE do not respond well to treatment with AEDs
[1]. These individuals become candidates for surgical treatment after an extensive clinical
Fig 3. Variable importance plot. Each point represents the mean decreased accuracy estimate (y-axis), for each
clinical variable and SNP genotype selected by the model (x-axis). Letter codes (AB and BB), after SNP name,
indicate heterozygote and the alternative homozygote allele for each SNP, respectively.
doi:10.1371/journal.pone.0169214.g003
Predicting Drug Response in Mesial Temporal Lobe Epilepsy
PLOS ONE | DOI:10.1371/journal.pone.0169214 January 4, 2017 9 / 15
investigation, which includes several trials of different combinations of AEDs. Therefore, if
one could better predict which patients are less likely to respond to AED treatment, pre-opera-
tive clinical investigation could be shortened, offering a timely opportunity for patients to
become seizure-free after appropriate surgical treatment. In this context, the only characteris-
tic available to date, to be used as predictor of refractory seizures in patients with MTLE, is the
presence of HS on MRI [1, 37].
Over the past few years, there has been a significant increase in the number of US-FDA
approved drugs containing molecular biomarker information [19], which includes population-
and genotype-specific recommended dosage. It has been proposed that genetic factors could
be involved in determining the lack of response to AEDs in patients with MTLE [1, 3]. Indeed,
a number of studies have shown genetic association of several SNPs in candidate genes and
AED response in patients with epilepsy [14–18]. However, all of these studies were either not
replicated or lacked analysis of their clinical validity, especially in comparison with the previ-
ously established predictive value of HS in discriminating refractory MTLE patients. In addi-
tion, no previous study examined simultaneously the role of SNPs in more than one candidate
gene influencing AED response.
Population stratification is a real concern in population-based association studies or com-
parison of genotype distribution among groups. It could lead to spurious results due to allele
frequency differences between groups attributable to genetic diversity in the background pop-
ulation, regardless of outcome status [38]. However, self-reported race in Brazilian individuals
are usually associated with skin colour, and several studies have showed that skin colour is not
associated with genetic structure in Brazilian population [39]. In this case, random molecular
markers across the genome could be useful to evaluate differences in genetic structure between
cases and controls. Furthermore, studies showed that inter-chromosomal population structure
is an important confounding factor [29]. In our study, we applied additional 98 randomly
Fig 4. ABCC2 mRNA relative quantification. The boxplots include dots for each sample, showing the relative
quantification of ABCC2 mRNA, in terms of 2-ΔΔCT (y-axis), between hippocampal tissue from refractory MTLE
patients and control autopsies.
doi:10.1371/journal.pone.0169214.g004
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chosen SNPs based on the chromosomal location of the candidate genes studied (chromosomes
2, 7, 10, 15, and 22). In addition, we performed the analysis with all five chromosomes combined
and each chromosome separately. Our results showed that the between-groups variance compo-
nent for all five chromosomes combined was 0.3%, while chromosome 22 separately reached
2.5%, which could be due to small number of SNPs used for the analysis. Population studies
have shown that the among-groups variance component worldwide was 5.4%, ranging from
0.7% (Europe) to 3.1% (Africa) [34]. Furthermore, in this study, Fst values were lower than 0.05
for all chromosomes combined. Therefore, the two groups of patients analysed in the present
study derive from the same population, allowing for unbiased comparisons between them.
There is a fundamental limitation when interpreting the results from most genetic associa-
tion studies since they use hypothesis-testing approaches, which presents models that have the
best descriptive features for the dataset studied, but lack predictive power to be applied to
other samples [40]. Therefore, the lack of replicability in these association studies is expected,
since a positive association in a sample cannot be used to predict results in another trial with a
different dataset [40]. This limitation has been especially true for studies related to AED
response in epilepsy. For instance, SNP rs1045642 (c.3435T>C), within ABCB1, was initially
associated with refractory epilepsy, but several other studies could not replicate the results [16,
17]. Indeed, our study showed that SNP rs1045642 presented low importance (MDA = 5.2), to
the prediction model proposed (S5 Table).
In order to overcome these limitations, we used a cross-validation approach, which opti-
mises the parameters in a statistical model according to the analyst interest, extending the
applicability of the fitted model to additional situations. In this context, we used the method to
determine the parameter that maximises the discriminatory power of random forests when
assessing the AED drug response in patients with MTLE. Given the strategy of splitting the
dataset into two parts (training and test sets), we can apply our model to individuals that are
not part of our original dataset and obtain responses that are more accurate than those pro-
vided by descriptive models. The random forests algorithm is an ensemble learning approach
based on building several decision trees combined with a voting system to perform classifica-
tions. It is an improvement of decision trees as it overcomes the problem of overfitting [35].
Therefore, the LOOCV approach with random forests algorithm enabled us to identify the
model with the best discriminatory properties to identify patients with AED refractory MTLE.
Applying these to our dataset showed that the best parameters for discriminating patients with
poor response to AEDs include the presence of HS detected by MRI and genotypic informa-
tion from 11 candidate genes. In addition, we demonstrated that factors such as gender, ante-
cedent of febrile seizures, and age of seizure onset are not present in the best prediction model.
Although we did not replicate these results in a second cohort, the LOOCV statistical approach
is able to minimize this limitation. Indeed, one recent review showed that, among 55 predic-
tion studies, nine used cross-validation approach as independent validation, and only six vali-
dated in a second cohort [41]. In addition, it would be interesting to know whether specific
SNPs may be associated with AED response for different drugs. However, our study was
underpowered to determine whether such specific correlation exists.
Several studies have observed an improvement of discriminatory accuracy when combining
clinical variables with SNP information [41], including breast cancer(from 0.58 to 0.61) [42],
nasopharyngeal carcinoma (from 0.68 to 0.74) [43], and venous thrombosis (from 0.77 to
0.82)[44]. In our study, we demonstrate that by including SNP information in addition to only
clinical and imaging parameters, there was a significant increase in the discriminatory accu-
racy from 0.4568 to 0.8177. This notable increase of the discriminatory accuracy could be due
to our focus on the specific seizure aetiology (MTLE), which is an advantage under a study
design where different epilepsy phenotypes are mixed. In this case, we could hypothesize that
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the mechanisms controlling drug response could be different in different forms of epilepsies,
and this line of study could provide new insights into mechanisms of drug resistance.
Although additional clinical covariates could be incorporated in prediction models, those used
in our study are the ones usually most easily available to clinicians.
Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by
the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov) [19]. However, SNPs
in CYP2C9 and CYP2D6 [19] present an average MAF = 0.06, significantly limiting their use in
clinical practice, since they can only be detected in a small fraction of the population. In con-
trast, the SNP set found in our model has an average MAF = 0.20, setting a clear advantage for
its use in clinical practice, mainly because this average MAF indicates that our SNP set presents
a high heterozygosity, which could be used in small sample sizes.
Previous studies have described an increase in multiple drug expression genes in patients
with refractory epilepsy and MTLE patients [6, 7]. We also observed an increase in ABCC2
gene expression in hippocampal tissue from MTLE patients, compared with control autopsies.
Therefore, our study strengthens the hypothesis that ABCC2 could influence AED drug
response in patients with MTLE.
In conclusion, we have shown that clinical variables in combination with SNP genotypes
located in 11 genes influencing drug transport and metabolism can more accurately predict
the response to drug therapy in patients with MTLE. Applying this model in clinical practice
would allow a patient likely to develop resistance to treatment with AEDs to be identified
sooner, thus benefiting from an earlier indication of epilepsy surgery. To the best of our
knowledge, we demonstrated for the first time that genetic information improves the predic-
tion of response to AED treatment in patients with MTLE, and could be used in clinical prac-
tice for decision-making.
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